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Clinical Implications
! This analysis of a phase 2a study shows that the addition
of dupilumab to mometasone furoate nasal spray
improves clinical and patient-reported outcomes in
patients with chronic rhinosinusitis with nasal polyps and
comorbid asthma.
TO THE EDITOR:
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a
common inﬂammatory condition affecting the upper airways,
with chronic symptoms such as nasal congestion, partial (hypo-
smia) or total (anosmia) loss of smell, anterior/posterior rhinor-
rhea, and mild facial pain.1 As many as 66% of patients with
CRSwNP have comorbid asthma and suffer from more severe
nasal obstruction, higher levels of lower airway inﬂammation,
and worse asthma control than those without CRS.2,3 Thus,
patients with CRSwNP and comorbid asthma have a high disease
burden, seriously impacting health-related quality of life
(HRQoL).2,3 Markers of type 2-mediated inﬂammation and
antibody production (eg, IL-5, IgE) are associated with both
CRSwNP and asthma pathogenesis.2
Dupilumab, a fully human VelocImmune-derived4,5 mono-
clonal antibody, blocks the shared receptor component for IL-4
and IL-13, thus inhibiting signaling of both IL-4 and IL-13, key
drivers of type 2 diseases such as atopic dermatitis, asthma, and
allergic rhinitis.6 In a 16-week phase 2a study in adults with
CRSwNP refractory to intranasal corticosteroids (INCS), adding
dupilumab to mometasone furoate nasal spray (MFNS) reduced
nasal polyp burden versusMFNS alone and signiﬁcantly improved
nasal congestion and airﬂow, sense of smell, HRQoL, and other
nasal symptoms.7 We present a subgroup analysis of patients with
CRSwNP and comorbid asthma from this study, examining the
effect of dupilumab on patient-reported outcomes (PROs) for
CRSwNP and asthma, and inﬂammatory biomarkers.
This randomized, double-blind, placebo-controlled study
included a 4-week run-in and 16-week blinded-treatment
period.5 Patients aged " 18 to 65 years with bilateral NP and
chronic symptoms of rhinosinusitis despite INCS treatment " 2
months, and " 2 rhinosinusitis symptoms (nasal obstruction,
nasal discharge, facial pain/pressure, reduction/loss of smell),
were randomized 1:1 to dupilumab 300 mg weekly or placebo, as
add-on to MFNS for 16 weeks.
The effect of dupilumab on various NP outcomes in patients
with CRSwNP has previously been published.7 Of 60 patients
randomized, 35 (16 dupilumab, 19 placebo) had CRSwNP and
comorbid asthma. Baseline demographics and disease character-
istics were similar between the study groups (Table E1, available
in this article’s Online Repository at www.jaci-inpractice.org).
TABLE I. ACQ-5 scores at baseline and change from baseline at week 16 in patients with CRSwNP and comorbid asthma
ACQ-5† Measure
Mean score (SD) at baseline LS mean change (SE) from baseline to week 16
LS mean difference
for dupilumab vs placebo
(95% CI)
Placebo/MFNS
(n [ 19)
Dupilumab/MFNS
(n [ 16)
Placebo/MFNS
(n [ 12)
Dupilumab/MFNS
(n [ 15)
Total
overallz
Total 1.63 (0.87) 1.55 (1.11) # 0.10 (0.20) # 1.19 (0.19) # 1.09 (# 1.54, # 0.63)***
Item 1x Woken at night by asthma 1.00 (1.10) 0.88 (1.45) 0.08 (0.24) e0.91 (0.23) e0.99 (e1.55, e0.42)**
Item 2x Awake in morning with
asthma symptoms
2.00 (1.37) 1.69 (1.25) 0.01 (0.22) e1.46 (0.20) e1.46 (e1.94, e0.99)***
Item 3x Limited in activities 1.38 (1.20) 1.25 (1.13) e0.11 (0.23) e0.93 (0.21) e0.83 (e1.34, e0.32)**
Item 4x Shortness of breath 2.19 (1.33) 1.94 (1.24) e0.29 (0.29) e1.33 (0.27) e1.04 (e1.77, e0.31)**
Item 5x Wheezing time 1.56 (0.63) 2.00 (1.90) e0.54 (0.36) e1.50 (0.34) e0.96 (e1.81, e0.12)*
LS means (and corresponding P values) are based on the mixed-effects model with repeated measures.
ACQ-5 , 5-Item Asthma Control Questionnaire; CI, conﬁdence interval; CRSwNP, chronic rhinosinusitis with nasal polyps; LS, least squares; MCID, minimal clinically
important difference; MFNS, mometasone fuorate nasal spray; SD, standard deviation; SE, standard error.
*P < .05 vs placebo.
**P < .01 vs placebo.
***P < .001 vs placebo.
†Recall period ¼ 1 wk; score range ¼ 0-6. Lower score indicates better control of asthma.
zWithin-group MCID of 0.5.
xWithin-patient MCID of 0.6.
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Mean (standard deviation) age was 49.4 (9.0) years; 14 patients
were men, and 13 patients (37.1%) had aspirin-exacerbated
respiratory disease (42.1% placebo, 31.3% dupilumab). At
baseline, patients had moderate-to-severe CRSwNP, and in-
ﬂammatory biomarker levels were generally similar across treat-
ment groups. Among patients with CRSwNP and comorbid
asthma, dupilumab-treated patients (vs placebo) showed a sig-
niﬁcant improvement in endoscopic NP score (P < .001), sense
of smell (P < .001), Lund-Mackay computed tomography total
score (P < .001), and signiﬁcant reduction in CRSwNP disease
severity (P < .001). Furthermore, a signiﬁcant improvement in
the total 22-item Sino-Nasal Outcome Test score at week 16 was
observed in dupilumab-treated patients (vs placebo) (P < .001).
Dupilumab versus placebo also produced signiﬁcant
improvements in forced expiratory volume in 1 second % pre-
dicted (P ¼ .04) and 5-item Asthma Control Questionnaire
(ACQ-5) total score (P < .001) exceeding the minimal clinically
important difference (MCID) of 0.5.7
In this study, we further assessed the effect of dupilumab on
HRQoL in patients with CRSwNP with comorbid asthma using
the 5-dimension EuroQoL questionnaire (EQ-5D) visual analog
scale (VAS) and 36-item Short-Form Health Survey (SF-36).
EQ-5D VAS provides a simple measure of the patient’s self-rated
health on a vertical virtual analog scale, with scores 0 to 100 mm
(worst-best imaginable health state).8 SF-36 comprises 8 do-
mains assessing physical functioning, social functioning, role
limitations due to physical and emotional problems, mental
health, energy/vitality, bodily pain, and general health percep-
tion. Two summary scores, the physical (PCS) and mental health
component summary, are calculated by the aggregation of the 8
SF-36 subscales, to evaluate the physical and mental health,
respectively (higher scores indicating better HRQoL).9 The
effects of dupilumab on the individual ACQ-5 scores (woken at
night by asthma, awake in morning with asthma symptoms,
limited in activities, shortness of breath, wheezing time), as well
as inﬂammatory biomarkers (eosinophils, eosinophil cationic
protein, thymus and activation-regulated chemokine, IgE, and
periostin), were also assessed.
Changes in clinical outcomes and PROs from baseline to week
16 in patients with CRSwNP and comorbid asthma were
reported as least-squares mean values and analyzed using a
mixed-effects model with a repeated-measures approach. An
unstructured correlation matrix was used to analyze within-
patient errors; there was no imputation for missing data. A
P value <.05 for the comparison between dupilumab and
placebo was considered statistically signiﬁcant.
For each of the individual ACQ-5 scores, a signiﬁcant differ-
ence between treatment groups was observed from baseline to
week 16 in favor of dupilumab (Table I). ACQ-5 responder rate
(MCID " 0.5) was signiﬁcantly higher (P ¼ .038) in dupilumab-
treated patients (62.5%) versus placebo (15.8%). Dupilumab
versus placebo produced signiﬁcant improvements in health sta-
tus, measured by EQ-5D VAS (P < .001; Figure 1, A). In
dupilumab-treated patients, signiﬁcant improvements from
baseline were observed in 5 SF-36 domains (general health,
physical functioning, role-physical, social functioning, and
vitality) and PCS (P < .05) (Figure 1, B). For placebo, change
from baseline was statistically signiﬁcant (P < .05) in only 2 do-
mains (role-physical and social functioning) and PCS (Figure 1,
B). Dupilumab-treated patients (vs placebo) showed a signiﬁcantly
greater reduction from baseline in serum (P ¼ .002) and nasal
(P ¼ .04) secretion levels of total IgE (Table E2, available in this
article’s Online Repository at www.jaci-inpractice.org).
This subgroup analysis of patients with CRSwNP and co-
morbid asthma extends the previously reported observations that
adding dupilumab to MFNS treatment improves nasal polyp
burden, asthma control, lung function, and HRQoL.7 The ef-
fects of dupilumab on CRSwNP-speciﬁc clinical outcomes and
PROs in patients with asthma were similar in magnitude to those
reported for the overall population.7 Focusing on PROs, the
clinical beneﬁt of dupilumab in patients with CRSwNP and
comorbid asthma was observed for CRSwNP disease and
symptom severity, and asthma control (assessed by ACQ-5 total
and individual item scores) reﬂecting a reduced impact of asthma
on daily activities and an improved HRQoL. Signiﬁcant
FIGURE 1. Change in generic HRQoL outcomes: least-squares
mean change from baseline in EQ-5D self-rated health VAS
(mm) score at week 16 (A), and in SF-36 individual domain scores
at week 16 (B). LS means (and corresponding P values) are based
on the mixed-effects model with repeated measures. Blue aster-
isks indicate statistically significant improvement from baseline
within dupilumab-treated patients (P < .05). Gray asterisks indi-
cate statistically significant improvement from baseline within
placebo-treated patients (P < .05). BP, Bodily pain; EQ-5D, 5-
dimension EuroQoL questionnaire;GH, general health;HRQoL,
health-related quality of life;MCS, mental component summary;
MFNS, mometasone furoate nasal spray; MH, mental health;
PCS, physical component summary;PF, physical functioning;RE,
role-emotional; RP, role-physical; SE, standard error; SF, social
functioning;SF-36, 36-item Short-Form Health Survey;VAS, vi-
sual analog scale;VT, vitality.
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improvement from baseline in general health perception, physical
functioning, and vitality was only observed with dupilumab
treatment and not in the placebo arm.
In conclusion, treatment with dupilumab was associated with
an improvement of both clinical and patient-reported NP-spe-
ciﬁc outcomes, and asthma-speciﬁc outcomes in patients with
CRSwNP and comorbid asthma.
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TABLE E1. Baseline demographics and disease characteristics of patients with CRSwNP with comorbid asthma
Placebo/MFNS (n [ 19) Dupilumab/MFNS (n [ 16)
Patient characteristic
Age, mean (SD), y 47.7 (9.9) 51.4 (7.6)
Male, n (%) 7 (36.8) 7 (43.8)
Duration of CRSwNP, mean (SD), y 11.32 (8.93) 8.95 (6.33)
Duration of asthma, mean (SD), y 20.15 (17.40) 15.46 (12.13)
Patients with aspirin-sensitive asthma, n (%) 8 (42.1) 5 (31.3)
Baseline measures of CRSwNP
Nasal polyps endoscopic score, range 0-8*, mean (SD) 5.53 (1.02) 5.94 (0.85)
CT Lund-Mackay total score, range 0-24*, mean (SD) 19.95 (5.65) 19.07 (4.23)
CRSwNP disease severity VAS (0-10 cm)*, mean (SD) 6.66 (2.36) 6.23 (2.73)
Daily congestion/obstruction score (0-3)† 1.67 (0.74) 1.43 (0.73)
Daily AM loss of smell score† (0-3)† 2.93 (0.24) 2.47 (0.96)
SNOT-22 total score (0-110), mean (SD)* 43.63 (20.66) 40.63 (16.26)
Baseline measures of asthma
ACQ-5 total score, mean (SD) 1.63 (0.87) 1.55 (1.11)
Baseline FEV1, mean (SD), % predicted 79.76 (14.55) 82.19 (17.71)
Baseline levels of biomarkers
Serum blood eosinophil count, mean (SD), 109/L 0.55 (0.83) 0.51 (0.25)
Serum ECP, mean (SD), ng/mL 37.26 (48.33) 35.38 (26.27)
Nasal secretion ECP, mean (SD), ng/mL 16.47 (11.49) 41.80 (43.44)
Serum total IgE, mean (SD), IU/mL 233.06 (300.44) 167.13 (153.77)
Nasal secretion total IgE, mean (SD), IU/mL 7.53 (5.64) 20.93 (41.78)
Serum TARC, mean (SD), pg/mL 506.20 (422.59) 506.77 (340.29)
Serum periostin, mean (SD), ng/mL 72.86 (28.52) 80.42 (24.44)
Nasal secretion periostin, mean (SD), ng/mL 6.92 (5.44) 7.27 (5.78)
ACQ-5 , 5-item Asthma Control Questionnaire; AM, morning; CRSwNP, chronic rhinosinusitis with nasal polyps; CT, computed tomography; ECP, eosinophil cationic protein;
FEV1 , forced expiratory volume in 1 s; MFNS, mometasone fuorate nasal spray; SD, standard deviation; SNOT-22, 22-item Sino-Nasal Outcome Test; TARC, thymus and
activation-regulated chemokine; VAS, visual analog scale.
*Higher scores indicate worse status.
†Average of the last 7 d before randomization.
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